Horvat Aleksijević Lorena, Lončar Brzak Božana, Sikora Miroslav, Škrinjar Ivana, Brailo Vlaho, Andabak Rogulj Ana, Aleksijević Marko, Vidović Juras Danica
Health Centre Osijek-Baranja County, Park kralja P. Krešimira IV/6, 31000 Osijek, Croatia.
Department of Oral Medicine, School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Dent J (Basel). 2025 Jul 23;13(8):336. doi: 10.3390/dj13080336.
Burning mouth syndrome (BMS) is a chronic, painful, idiopathic condition of the oral cavity, characterized by the absence of visible pathological changes on the oral mucosa and normal laboratory findings. Recent evidence from the literature supports the classification of BMS as a neuropathic condition. It has been proposed that oxidative stress may contribute to neuropathic pain. N-acetylcysteine (NAC) is an antioxidant that exhibits neuroprotective properties. The aim of the study was to evaluate the efficacy of N-acetyl cysteine in the treatment of burning mouth syndrome (BMS). Eighty female patients with previously diagnosed BMS were randomly assigned to one out of two groups. One group received N-acetyl cysteine (600 mg/twice a day) and the other received placebo, for an eight-week period. The outcome was measured by the Oral Health Impact Profile-14 (OHIP-14) quality of life questionnaire and Numeric Pain Rating Scale, for burning and discomfort, both before and after completing the therapy. Both groups experienced a significant reduction in burning and discomfort sensations, along with a significant improvement in oral health-related quality of life. However, the difference between the treatment and control group was not statistically significant. NAC does not significantly improve the oral health-related quality of life, burning sensations, and discomfort in BMS subjects compared to placebo.
灼口综合征（BMS）是一种口腔慢性、疼痛性、特发性疾病，其特征为口腔黏膜无明显病理变化且实验室检查结果正常。文献中的最新证据支持将BMS归类为神经病理性疾病。有人提出氧化应激可能导致神经病理性疼痛。N-乙酰半胱氨酸（NAC）是一种具有神经保护特性的抗氧化剂。本研究的目的是评估N-乙酰半胱氨酸治疗灼口综合征（BMS）的疗效。80名先前被诊断为BMS的女性患者被随机分为两组。一组接受N-乙酰半胱氨酸（600毫克/每日两次），另一组接受安慰剂，为期8周。在治疗前后，通过口腔健康影响程度量表-14（OHIP-14）生活质量问卷和数字疼痛评分量表来衡量灼痛和不适的结果。两组的灼痛和不适感觉均显著减轻，口腔健康相关生活质量也显著改善。然而，治疗组与对照组之间的差异无统计学意义。与安慰剂相比，NAC并未显著改善BMS患者的口腔健康相关生活质量、灼痛感觉和不适。
